X @The Economist

“Biopharmaceutical innovation is a global public good. But it is both risky and expensive to carry out,” writes Tomas Philipson. The former chair of America’s Council of Economic Advisers argues for reforms to European drug pricing https://t.co/O3nvcRVuN1 ...